NZ736194A - A vaccine composition and uses thereof - Google Patents

A vaccine composition and uses thereof

Info

Publication number
NZ736194A
NZ736194A NZ736194A NZ73619416A NZ736194A NZ 736194 A NZ736194 A NZ 736194A NZ 736194 A NZ736194 A NZ 736194A NZ 73619416 A NZ73619416 A NZ 73619416A NZ 736194 A NZ736194 A NZ 736194A
Authority
NZ
New Zealand
Prior art keywords
crm
fusion
alum
crm197
neu
Prior art date
Application number
NZ736194A
Other languages
English (en)
Inventor
Ursula Wiedermann
Original Assignee
Biolife Science Qld Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015901375A external-priority patent/AU2015901375A0/en
Application filed by Biolife Science Qld Ltd filed Critical Biolife Science Qld Ltd
Publication of NZ736194A publication Critical patent/NZ736194A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/812—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/828—Stomach
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/16142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ736194A 2015-04-17 2016-04-15 A vaccine composition and uses thereof NZ736194A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2015901375A AU2015901375A0 (en) 2015-04-17 A vaccine composition and uses thereof
PCT/AU2016/050275 WO2016164980A1 (en) 2015-04-17 2016-04-15 A vaccine composition and uses thereof

Publications (1)

Publication Number Publication Date
NZ736194A true NZ736194A (en) 2022-08-26

Family

ID=57125491

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ736194A NZ736194A (en) 2015-04-17 2016-04-15 A vaccine composition and uses thereof

Country Status (13)

Country Link
US (1) US10532090B2 (enExample)
EP (1) EP3283105B1 (enExample)
JP (1) JP6957448B2 (enExample)
KR (1) KR102372615B1 (enExample)
CN (1) CN108025061B (enExample)
AU (1) AU2016250289B2 (enExample)
ES (1) ES2908071T3 (enExample)
NZ (1) NZ736194A (enExample)
RS (1) RS63080B1 (enExample)
RU (1) RU2726411C2 (enExample)
SG (1) SG11201708247XA (enExample)
TW (1) TWI740823B (enExample)
WO (1) WO2016164980A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210346484A1 (en) * 2017-12-11 2021-11-11 Medizinische Universitaet Wien Method of producing a vaccine composition and uses thereof
CA3090552A1 (en) * 2018-02-07 2019-08-15 Imugene Limited A vaccine composition and uses thereof
WO2022133447A1 (en) * 2020-12-16 2022-06-23 Dynavax Technologies Corporation Method for quantifying cpg-containing oligonucleotides in formulations comprising alum

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0739984A1 (en) * 1995-04-26 1996-10-30 San Tumorforschungs-Gmbh Bivalent polypeptides containing at least two domains
GB9808932D0 (en) * 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
JP4658423B2 (ja) * 1999-08-03 2011-03-23 ザ オハイオ ステイト ユニバーシティ Ｈｅｒ−２タンパク質に対する免疫反応性を増強するためのポリペプチドおよびポリヌクレオチド
EP1236740B1 (de) 2001-02-28 2012-07-18 Bio Life Science Forschungs- und Entwicklungsges.m.b.H. Vakzine gegen Krebserkrankungen, die mit dem HER-2/neu Onkogen assoziiert sind
WO2005021710A2 (en) * 2003-06-02 2005-03-10 University Of Miami Chimeric molecules and methods of use
EP1844788B1 (en) 2006-04-13 2010-07-14 Bio Life Science Forschungs- und Entwicklungsges.m.b.H. HER-2/neu multi-peptide vaccine
EP2292258A1 (en) * 2009-08-18 2011-03-09 Pevion Biotech Ltd. Multiepitope vaccine for Her2/neu-associated cancers
EP2659906A1 (en) * 2012-05-01 2013-11-06 Affiris AG Compositions
ES2528109T3 (es) * 2012-05-31 2015-02-04 Innavirvax Compuestos inmunogénicos que comprenden péptido gp41 de VIH acoplado a proteína portadora CRM197
EP3166646A4 (en) * 2014-07-07 2018-03-07 Duke University Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same

Also Published As

Publication number Publication date
US10532090B2 (en) 2020-01-14
EP3283105A1 (en) 2018-02-21
CN108025061A (zh) 2018-05-11
TW201705978A (zh) 2017-02-16
EP3283105A4 (en) 2018-12-19
JP2018511659A (ja) 2018-04-26
SG11201708247XA (en) 2017-11-29
JP6957448B2 (ja) 2021-11-02
KR20180003560A (ko) 2018-01-09
RU2017137502A3 (enExample) 2019-09-16
KR102372615B1 (ko) 2022-03-08
RS63080B1 (sr) 2022-04-29
CN108025061B (zh) 2022-02-15
AU2016250289B2 (en) 2017-03-02
US20170119867A1 (en) 2017-05-04
RU2726411C2 (ru) 2020-07-14
BR112017021981A2 (pt) 2018-07-10
HK1248536A1 (zh) 2018-10-19
TWI740823B (zh) 2021-10-01
EP3283105B1 (en) 2022-01-26
ES2908071T3 (es) 2022-04-27
RU2017137502A (ru) 2019-05-17
AU2016250289A1 (en) 2017-01-05
WO2016164980A1 (en) 2016-10-20

Similar Documents

Publication Publication Date Title
US8470333B2 (en) Chimeric peptides comprising HER-2 B-cell epitopes and T-helper epitopes
US20170143810A1 (en) Immunogenic glycopeptides, composition comprising the glycopeptides and use thereof
TW202212348A (zh) 用於治療阿茲海默症之β類澱粉蛋白疫苗
TW202227464A (zh) 治療阿茲海默氏症之多表位疫苗
CA2763486A1 (en) Casb7439 constructs
CN117751132A (zh) 用于治疗阿尔兹海默氏病的tau疫苗
US12311019B2 (en) Vaccine composition and uses thereof
US10532090B2 (en) Vaccine composition and uses thereof
TW202227465A (zh) 治療突觸核蛋白病症之α－突觸核蛋白疫苗
US20180264093A1 (en) Immunogenic glycopeptide compounds, pharmaceutical compositions and uses thereof
US20210346484A1 (en) Method of producing a vaccine composition and uses thereof
HK1248536B (en) A vaccine composition and uses thereof
BR112017021981B1 (pt) Composição de vacina e usos da mesma
CN113318225A (zh) 肿瘤免疫增强剂及其制法和应用

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 APR 2024 BY CPA GLOBAL

Effective date: 20230303

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 APR 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20240301

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 APR 2026 BY DENNEMEYER + CO. SARL

Effective date: 20250408